US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
US5843941A
(en)
|
1993-05-14 |
1998-12-01 |
Genentech, Inc. |
Ras farnesyl transferase inhibitors
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
EP0951541B1
(fr)
|
1995-07-31 |
2005-11-30 |
Urocor, Inc. |
Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
AU751188C
(en)
|
1997-05-28 |
2005-06-30 |
Aventis Pharmaceuticals Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドglp−1アゴニスト
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
DE60032910T3
(de)
|
1999-05-05 |
2010-07-29 |
Institut Curie |
Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3
|
US7169778B2
(en)
|
1999-09-15 |
2007-01-30 |
Warner-Lambert Company |
Pteridinones as kinase inhibitors
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
WO2002076985A1
(fr)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives
|
DE60223720T2
(de)
|
2001-12-18 |
2008-10-30 |
Merck & Co., Inc. |
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
|
JP4498741B2
(ja)
|
2001-12-24 |
2010-07-07 |
アストラゼネカ アクチボラグ |
オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
CA2480800C
(fr)
|
2002-04-08 |
2008-09-23 |
Mark T. Bilodeau |
Inhibiteurs de l'activite akt
|
US7074534B2
(en)
|
2002-07-10 |
2006-07-11 |
E. I. Du Pont De Nemours And Company |
Polymeric charge transport compositions and electronic devices made with such compositions
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
KR20120032574A
(ko)
|
2002-10-03 |
2012-04-05 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
DE602004021558D1
(de)
|
2003-01-17 |
2009-07-30 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
EP1620413A2
(fr)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Composes, compositions et procedes
|
EP1628666B1
(fr)
|
2003-05-14 |
2015-09-23 |
NeuroGenetic Pharmaceuticals, Inc. |
Composes et leurs utilisations pour la modulation de l'amyloide-beta
|
WO2004104003A1
(fr)
|
2003-05-23 |
2004-12-02 |
Zentaris Gmbh |
Nouvelles pyridopyrazines et leur utilisation en tant que modulateurs de kinases
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
WO2005007099A2
(fr)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Inhibiteurs de la pkb utilises comme agents antitumoraux
|
US7339065B2
(en)
|
2003-07-21 |
2008-03-04 |
Bethesda Pharmaceuticals, Inc. |
Design and synthesis of optimized ligands for PPAR
|
WO2005012288A1
(fr)
|
2003-08-01 |
2005-02-10 |
Genelabs Technologies, Inc |
Derives de l'imidazole bicycliques diriges contre les flaviviridae
|
AU2004283479A1
(en)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
JP4890255B2
(ja)
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
KR101118582B1
(ko)
|
2003-11-20 |
2012-02-27 |
얀센 파마슈티카 엔.브이. |
폴리(adp-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
|
AU2004295050A1
(en)
|
2003-11-24 |
2005-06-16 |
F.Hoffmann-La Roche Ag |
Pyrazolyl and imidazolyl pyrimidines
|
EP2228369A1
(fr)
|
2003-12-23 |
2010-09-15 |
Astex Therapeutics Ltd. |
Derives de pyrazole comme modulateurs de proteine kinase
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
CA2577275A1
(fr)
|
2004-08-31 |
2006-03-09 |
Astrazeneca Ab |
Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf
|
AU2005293835A1
(en)
|
2004-10-14 |
2006-04-20 |
F. Hoffmann-La Roche Ag |
1,5-Naphthyridine azolidinones having CDK1 antiproliferative activity
|
EP1659175A1
(fr)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Altérations des kératoses séborrhéiques et applications dérivées
|
EP2650010A1
(fr)
|
2004-12-24 |
2013-10-16 |
Spinifex Pharmaceuticals Pty Ltd |
Procédé de traitement de la prophylaxie
|
NZ556686A
(en)
|
2005-02-14 |
2010-01-29 |
Bionomics Ltd |
Novel tubulin polymerisation inhibitors
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
EP2439272A3
(fr)
|
2005-05-09 |
2013-07-31 |
Ono Pharmaceutical Co., Ltd. |
Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
|
CA2606017A1
(fr)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
Inhibiteurs de la tyrosine kinase
|
AU2006247315A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
JP5226513B2
(ja)
|
2005-08-26 |
2013-07-03 |
メルク セローノ ソシエテ アノニム |
ピラジン誘導体及びその使用
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
EP1957487A1
(fr)
|
2005-11-11 |
2008-08-20 |
AEterna Zentaris GmbH |
Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases
|
EP1790342A1
(fr)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
|
WO2007061130A1
(fr)
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
Agent antitumeur pour myelomes multiples
|
NZ568807A
(en)
|
2005-12-21 |
2011-05-27 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
EP2024342A2
(fr)
|
2006-05-01 |
2009-02-18 |
Pfizer Products Incorporated |
Composés hétérocycliques 2-amino-substitués à cycles fusionnés
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
US20100234347A1
(en)
|
2006-05-24 |
2010-09-16 |
Boehringer Ingelheim Internationl Gmbh |
Substituted Pteridines substituted with a Four-Membered Heterocycle
|
SG172698A1
(en)
|
2006-06-12 |
2011-07-28 |
Trubion Pharmaceuticals Inc |
Single-chain multivalent binding proteins with effector function
|
EP2044027A2
(fr)
|
2006-07-03 |
2009-04-08 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Composés bicycliques fusionnés interagissant avec le récepteur histamine h4
|
WO2008060907A2
(fr)
|
2006-11-10 |
2008-05-22 |
Bristol-Myers Squibb Company |
Nouveaux inhibiteurs de la kinase
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
1,5−ナフチリジン化合物及び有機発光素子
|
CA2672828A1
(fr)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Procedes de traitements
|
CA2673736A1
(fr)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Composes et procedes pour la modulation de kinases et indications pour celle-ci
|
MX2009006627A
(es)
|
2006-12-22 |
2009-08-12 |
Novartis Ag |
Quinazolinas para la inhibicion de pdk1.
|
AR064491A1
(es)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
WO2008109369A2
(fr)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
EP1990342A1
(fr)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Dérivés de pyridopyrazine, processus de fabrication et utilisations correspondantes
|
TW200902008A
(en)
|
2007-05-10 |
2009-01-16 |
Smithkline Beecham Corp |
Quinoxaline derivatives as PI3 kinase inhibitors
|
JP2010529031A
(ja)
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害剤としてのナフチリジン誘導体
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
RU2462454C2
(ru)
|
2007-06-20 |
2012-09-27 |
Мицубиси Танабе Фарма Корпорейшн |
Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение
|
JP5548123B2
(ja)
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−{ジフルオロ[6−(1−メチル−1H−ピラゾル−4−イル)[1,2,4]トリアゾロ[4,3−b]ピリダジン−3−イル]メチル}キノリンの多形および水和物の形態、塩、ならびに製造方法
|
JP2010532758A
(ja)
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
組み合わせ抗癌療法
|
WO2009020990A1
(fr)
|
2007-08-08 |
2009-02-12 |
Smithkline Beecham Corporation |
Dérivés de 2-[(2-{phénylamino}-1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide en tant qu'inhibiteur d'igf-1r pour le traitement du cancer
|
WO2009019518A1
(fr)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Composés de pyrimidine ayant un effet inhibiteur du fgfr
|
JP2010535804A
(ja)
|
2007-08-09 |
2010-11-25 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害薬としてのキノキサリン誘導体
|
WO2013173485A1
(fr)
|
2012-05-15 |
2013-11-21 |
Predictive Biosciences, Inc. |
Détection de cancers de la vessie
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EA020777B1
(ru)
|
2007-11-16 |
2015-01-30 |
Инсайт Корпорейшн |
4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
|
CA2722992A1
(fr)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Administration sequentielle d'agents de chimiotherapie pour le traitement du cancer
|
MY155535A
(en)
|
2008-05-23 |
2015-10-30 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
|
US8592448B2
(en)
|
2008-11-20 |
2013-11-26 |
OSI Pharmaceuticals, LLC |
Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
|
EP2389376A1
(fr)
|
2009-01-21 |
2011-11-30 |
Basilea Pharmaceutica AG |
Nouveaux antibiotiques bicycliques
|
US20110288090A1
(en)
|
2009-02-02 |
2011-11-24 |
Armstrong Donna J |
Inhibitors of AKT Activity
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CN106905232B
(zh)
|
2009-06-12 |
2019-09-27 |
Abivax公司 |
用于治疗过早衰老和尤其是早衰的化合物
|
CN102656163B
(zh)
|
2009-09-03 |
2016-01-13 |
拜奥埃内杰尼克斯公司 |
抑制pask的杂环化合物
|
US9340528B2
(en)
|
2009-09-04 |
2016-05-17 |
Bayer Pharma Aktiengesellschaft |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
EP2332939A1
(fr)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Nouveaux dérivés de naphtyridine et l'utilisation associée en tant qu'inhibiteurs de kinase
|
KR102113960B1
(ko)
|
2010-03-30 |
2020-05-21 |
베르선 코포레이션 |
트롬빈 억제제로서의 다중치환된 방향족 화합물
|
GB201007286D0
(en)
*
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
US8513421B2
(en)
|
2010-05-19 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
JP5894980B2
(ja)
|
2010-05-24 |
2016-03-30 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CN102532141A
(zh)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
|
WO2012104776A1
(fr)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Dérivés hétérocycliques inédits
|
MX2013008833A
(es)
|
2011-02-02 |
2013-12-06 |
Amgen Inc |
Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
|
CN106619647A
(zh)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
WO2012118492A1
(fr)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
WO2013032951A1
(fr)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Entités chimiques, compositions et procédés
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP2757885B1
(fr)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Entités chimiques, compositions, et procédés spécifiques
|
EP2761300A4
(fr)
|
2011-09-27 |
2015-12-02 |
Univ Michigan |
Fusions de gènes récurrentes dans le cancer du sein
|
US20140235643A1
(en)
|
2011-10-04 |
2014-08-21 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
EA023935B1
(ru)
|
2011-10-28 |
2016-07-29 |
Новартис Аг |
Производные пурина и их применение для лечения заболевания
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
WO2013088191A1
(fr)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
JP6107812B2
(ja)
*
|
2012-03-08 |
2017-04-05 |
アステラス製薬株式会社 |
新規fgfr3融合体
|
US20150086584A1
(en)
|
2012-03-22 |
2015-03-26 |
University Of Miami |
Multi-specific binding agents
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
WO2014007369A1
(fr)
|
2012-07-05 |
2014-01-09 |
独立行政法人国立がん研究センター |
Gène fgfr2 hybride
|
JP6382194B2
(ja)
|
2012-07-24 |
2018-08-29 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
融合タンパク質およびその方法
|
US20150203589A1
(en)
*
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
US20140030259A1
(en)
|
2012-07-27 |
2014-01-30 |
Genentech, Inc. |
Methods of treating fgfr3 related conditions
|
CA2882292C
(fr)
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Traitement et diagnostic du melanome
|
EP2902489B9
(fr)
|
2012-09-27 |
2018-02-07 |
Chugai Seiyaku Kabushiki Kaisha |
Gène de fusion fgfr3 et médicament pharmaceutique ciblant celui-ci
|
AU2013337264B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014165422A1
(fr)
|
2013-04-02 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Test immunohistochimique pour détecter l'expression du ligand de mort programmée 1 (pd-l1) dans un tissu tumoral
|
US9777333B2
(en)
|
2013-04-05 |
2017-10-03 |
Life Technologies Corporation |
Gene fusion
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
EP3004380A2
(fr)
|
2013-05-27 |
2016-04-13 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Nouvelles translocations dans le cancer du poumon
|
WO2015006723A1
(fr)
|
2013-07-12 |
2015-01-15 |
The Regents Of The University Of Michigan |
Fusions de gènes récurrentes dans le cancer
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
TW201536291A
(zh)
|
2013-08-02 |
2015-10-01 |
Cephalon Inc |
單獨使用AXL/cMET抑制劑或與其它藥劑組合使用以治療多種癌症之方法
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
WO2015077717A1
(fr)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US20170002421A1
(en)
|
2013-12-23 |
2017-01-05 |
The General Hospital Corporation |
Methods and assays for determining reduced brca1 pathway function in a cancer cell
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016022056B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
|
DK3122359T3
(da)
|
2014-03-26 |
2021-03-08 |
Astex Therapeutics Ltd |
Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
CN106456764A
(zh)
|
2014-05-29 |
2017-02-22 |
免疫医疗有限公司 |
用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
|
WO2016004218A1
(fr)
|
2014-07-01 |
2016-01-07 |
Vicus Therapeutics, Llc |
Thérapies par association médicamenteuse contre le cancer et leurs procédés de fabrication et d'utilisation
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
JP6698084B2
(ja)
|
2014-08-08 |
2020-05-27 |
オンコクエスト インコーポレイテッドOncoquest Inc. |
がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびtlr3刺激
|
US20170239351A1
(en)
|
2014-08-11 |
2017-08-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
|
SG11201701710SA
(en)
|
2014-09-08 |
2017-04-27 |
Celgene Corp |
Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
|
EP3191126B1
(fr)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Thérapies combinées d'inhibiteurs d'alk
|
US20170275705A1
(en)
|
2014-09-15 |
2017-09-28 |
The Johns Hopkins University |
Biomarkers useful for determining response to pd-1 blockade therapy
|
JP6766037B2
(ja)
*
|
2014-09-26 |
2020-10-07 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Fgfr阻害剤による治療に応答性であるがん患者を同定する際の、fgfr変異遺伝子パネルの使用
|
MX2017004360A
(es)
|
2014-10-03 |
2017-06-26 |
Novartis Ag |
Terapias de combinacion.
|
WO2016061142A1
(fr)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Molécules d'anticorps de pd-l1 et leurs utilisations
|
JP6730271B2
(ja)
|
2014-10-29 |
2020-07-29 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
インターフェロンα2Bバリアント
|
WO2016094309A1
(fr)
|
2014-12-10 |
2016-06-16 |
Myosotis |
Inhibition de la signalisation de tnf en immunothérapie du cancer
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
JP2018502123A
(ja)
|
2015-01-20 |
2018-01-25 |
イミューンエクサイト, インコーポレイテッド |
癌免疫療法のための組成物及び方法
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
WO2016128912A1
(fr)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1
|
CA2976638A1
(fr)
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methodes, compositions et trousses pour le traitement du cancer
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
RU2737216C2
(ru)
|
2015-03-04 |
2020-11-26 |
Мерк Шарп Энд Дохме Корп. |
Комбинация антагониста pd-1 и эрибулина для лечения рака
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
KR20170124604A
(ko)
|
2015-03-20 |
2017-11-10 |
신닥스 파마슈티컬스, 인크. |
암 치료를 위한 hdac 억제제 및 항pd-1 항체의 조합
|
WO2016153839A1
(fr)
|
2015-03-20 |
2016-09-29 |
Merck Sharp & Dohme Corp. |
Combinaison d'un antagoniste de pd-1 et de vorinostat dans le traitement du cancer
|
EP3881860A1
(fr)
|
2015-03-26 |
2021-09-22 |
OncoSec Medical Incorporated |
Procédé pour le traitement de tumeurs malignes
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
AU2016249395B2
(en)
|
2015-04-17 |
2022-04-07 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-PD-1 antibody and another antibody
|
US20160347836A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
|
WO2016191751A1
(fr)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Traitement du cancer du poumon pd-l1 positif à l'aide d'un anticorps anti-pd-1
|
WO2016196389A1
(fr)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Traitement du néphrocarcinome
|
EA201792522A1
(ru)
|
2015-06-12 |
2018-05-31 |
Бристол-Майерс Сквибб Компани |
Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
|
CA2983597A1
(fr)
|
2015-06-25 |
2016-12-29 |
Immunomedics, Inc. |
Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoi nositide 3-kinase ameliorant considerablement un resultat therapeutique de cancer
|
WO2017004192A1
(fr)
|
2015-06-29 |
2017-01-05 |
Verastem, Inc. |
Compositions thérapeutiques, associations et procédés d'utilisation
|
GB201512869D0
(en)
|
2015-07-21 |
2015-09-02 |
Almac Diagnostics Ltd |
Gene signature for minute therapies
|
EP3325003A1
(fr)
|
2015-07-22 |
2018-05-30 |
HZNP Limited |
Combinaison d'un agent immunomodulateur avec les inhibiteurs de points de contrôle pd-1-ou pd-l1 dans le traitement du cancer
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
JP2019505476A
(ja)
|
2015-12-01 |
2019-02-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
組合せ処置およびその方法
|